News Stocks Lord's Mark Industries Partners with C-MET to Develop AI-Powered Breast Cancer Detection DeviceLord's Mark Industries Partners with C-MET to Develop AI-Powered Breast Cancer Detection Device
Lord's Mark Industries Limited has signed a Technology Transfer Agreement with C-MET to develop and commercialize an AI-powered, radiation-free wearable device for early breast cancer detection. The device uses advanced thermal sensors and AI-driven temperature mapping for non-invasive screening, targeting the global breast cancer diagnostics market projected to reach USD 12.88 billion by 2035. Commercial launch is expected by the end of the current calendar year, with plans for mass screening across India and international markets.
*this image is generated using AI for illustrative purposes only.
Lord's Mark Industries Limited has announced a strategic Technology Transfer Agreement (TTA) with the Centre for Materials for Electronic Technology (C-MET), an autonomous scientific society under the Ministry of Electronics and Information Technology (MeitY), Government of India. The partnership focuses on manufacturing and commercializing an AI-powered, radiation-free wearable device for early detection of breast cancer, marking a significant advancement in preventive healthcare technology.
Revolutionary Technology Features
The proposed device represents a breakthrough in breast cancer screening technology by integrating advanced thermal sensors with artificial intelligence-driven temperature mapping. This innovative approach enables the detection of early-stage abnormalities in a non-invasive and radiation-free manner, addressing major barriers associated with traditional mammography procedures. The device eliminates radiation exposure while providing a painless screening experience, making it more accessible to a broader population.
Partnership Details and Strategic Impact
| Parameter: | Details |
|---|---|
| Objective: | Manufacture world's first AI-powered, radiation-free breast screening wearable device |
| Technology Partner: | Centre for Materials for Electronic Technology (C-MET) |
| Technology Type: | High-precision thermal sensors with AI-driven temperature mapping |
| Market Projection: | Global breast cancer diagnostics market expected to reach USD 12.88 billion by 2035 |
| Commercial Launch: | Expected by end of current calendar year |
The collaboration leverages C-MET's research and development excellence alongside Lord's Mark's manufacturing and distribution capabilities. This strategic alliance aims to provide an affordable, portable, and scalable screening solution that can revolutionize breast cancer detection methodologies globally.
Market Potential and Commercialization Strategy
The company intends to commercialize this product for mass screening across India and international markets. With the global breast cancer diagnostics market projected to reach approximately USD 12.88 billion by 2035, this partnership positions Lord's Mark Industries at the forefront of the indigenous Med-Tech sector. The device's non-invasive nature and elimination of radiation exposure address significant concerns that often deter women from regular screening.
Management Perspective
Mr. Sachidanand Upadhyay, Managing Director, emphasized the significance of this collaboration, stating that it marks a defining step in the company's journey to build globally competitive, indigenous healthcare technologies. He highlighted how integrating C-MET's scientific expertise with the company's manufacturing strength enables a new paradigm in preventive diagnostics that is non-invasive, AI-driven, and truly accessible.
Innovation in Healthcare Technology
This partnership represents a significant milestone in India's healthcare technology landscape, combining government-backed research capabilities with private sector manufacturing expertise. The AI-powered device addresses critical gaps in current breast cancer screening methods by offering a solution that is both technologically advanced and patient-friendly. The radiation-free approach particularly addresses concerns about repeated exposure during regular screening protocols, potentially encouraging more frequent and early detection practices.
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
